Sun Yat-sen University clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
20 trials changed in the last 30 days: 1 stopped, 6 with notable changes, 13 with minor changes only.
- Minor: Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI Enrollment closed, study ongoing
-
Minor: 8 trials marked Unknown by the registry's verification sweep Changed
- Minor: TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Minor: Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2022); last known: Recruiting
- Minor: Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
- Minor: Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: NPBC · Nomogram for Predicting Biliary Complication Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: GOS and the Management of Hyperuricemia Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Posterior Continuous Curvilinear Capsulorhexis With or Without Anterior Vitrectomy Changed Registry marked status Unknown (sponsor has not verified the record since Nov 2021); last known: Recruiting
- Notable: PHM · IOP Lowering on Progressive HM Primary endpoint(s) modified
- Minor: Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy · Locally Advanced Pancreatic Cancer (SAGE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
- Notable: BCIRT-01 · Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Primary completion pushed from Dec 31, 2025 to Dec 31, 2026
- Notable: Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis · Nasopharyngeal Carcinoma Recruitment opened
- Notable: Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal Carcinoma Enrollment reduced: 514 → 298 participants
- Notable: ACTION-001 · TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk Recruitment opened
-
Minor: 2 trials marked Unknown by the registry's verification sweep Changed
- Minor: Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Active, Not Recruiting
- Minor: Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2023); last known: Recruiting
- Notable: Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma Primary and study completion dates pushed to Dec 30, 2026
- Minor: Failure of Immunotherapy With Vorolanib Combined With Everolimus Interventions modified
- Stopped: Validation of Insulin Dose Prediction Model Based on Artificial Intelligence Algorithm Trial terminated
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07938619 Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or… | Phase 2 | Not Yet Recruiting |
| 2026-11-13 | NCT07934927 A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in… | Phase 2 | Recruiting |
| 2026-11-10 | NCT07927452 Anatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular… | Recruiting | |
| 2026-11-09 | NCT07926672 Artificial Intelligence-Assisted Imaging for Diagnosis and Management of Focal Liver… | Recruiting | |
| 2026-11-06 | NCT07922915 Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell… | Phase 2 | Not Yet Recruiting |
| 2026-11-06 | NCT07922928 Toripalimab and Lenvatinib With or Without SBRT Before Surgery for Non-Clear Cell Kidney… | Phase 2 | Not Yet Recruiting |
| 2026-11-04 | NCT07915258 Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell… | Phase 2 | Not Yet Recruiting |
| 2026-11-04 | NCT07915271 Performance of Multi-Cancer Detection Test in Asymptomatic Patients With Neoplastic… | Not Yet Recruiting | |
| 2026-10-29 | NCT07902713 Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic… | Phase 2 | Not Yet Recruiting |
| 2026-10-29 | NCT07904156 A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant… | Phase 3 | Not Yet Recruiting |
Active trials by phase
| Early Phase 1 | 2 | |
| Phase 1 | 12 | |
| Phase 1/2 | 20 | |
| Phase 2 | 243 | |
| Phase 2/3 | 12 | |
| Phase 3 | 101 | |
| Phase 4 | 3 |
Not charted: 162 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 43
Head & Neck Cancer (125) · Colorectal Cancer (70) · Lung Cancer (50) · Liver Cancer (43) · Non-Small Cell Lung Cancer (NSCLC) (40) · Non-Hodgkin Lymphoma (38) · Breast Cancer (25) · Esophageal Cancer (20) · Heart Disease (17) · Kidney Cancer (14)
Get alerts when Sun Yat-sen University's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.